Virbac's Strong Half Is Really a Bet on Where the Next €100 Million Goes

An 18.8% H1 margin is the easy part; a hedged cost base, a deliberate H2 reinvestment and an M&A-first capital allocation are the actual signal.

VIRP.PA · Earnings Call · 2026-09-18

An 18.8% half, a 17% year — and the question that keeps coming back

Virbac SA reported H1 2026 with revenue of €768 million, up 7.4% at constant FX and scope, split 5% volume and 2% price. EBIT adjusted reached €144.2 million, or 18.8% of revenue, up 50 basis points; gross margin rose to 68.4% from 67.4%; net income climbed 6% to €87.1 million. Net debt of €196 million sits at 0.6x EBITDA. The obvious puzzle is why a company that just printed 18.8% guides to roughly 17% for the full year. It is a seasonality story — and a recurring one. Habib Ramdani framed it plainly: “We tend to have a higher EBIT adjusted margin during the first part of the year compared to the full year. So it has been the same.” — Habib Ramdani, Chief Financial Officer or Head of Finance (presenting financial results and detailed financial commentary) · 2026-09-18 Investors have asked a version of this every September — in the 2024 call the framing was whether guidance implied an “abnormally high drop in margin in the second semester versus first semester.” — Sandrine Brunel, Head of Corporate Communications · 2024-09-16 The related phasing of OpEx and R&D is a fixture of this name, not a new tell. What matters more is that management insists the H2 step-down is a choice. “We could hold things back in the second half if we wanted to keep the profit number where it is, but we want to continue to invest in the second half of the year to make sure we as well go into '27 and beyond...” — Paul Martingell, Executive (likely CEO or CFO) leading financial and strategic updates · 2026-09-18 That is an ambition statement disguised as conservatism.

Supercharge growth meets a hedged reality

The engine is the Supercharge platform family, growing around 12% in the half, with specialty +23%, pet food ~14%, nutritionals +20% and vaccines +8%. Thyronorm carried the specialty line and is running ahead of plan — “Thyronorm has added 1.4 points of growth during the semester.” — Habib Ramdani, Chief Financial Officer or Head of Finance (presenting financial results and detailed financial commentary) · 2026-09-18 India is again a standout, and Latin America more than offset Pacific softness. Here is where Virbac diverges sharply from the broader tape. The global theme stack for the last two quarters has been macro turbulence — Middle East impact, high fuel costs, and the entire tariff complex. Virbac is pointing the other way. On energy: “We have hedged in some of our countries, including France... So we are not really exposed for the next 2 years, neither on electricity nor on gas with a fixed price” — Habib Ramdani, Chief Financial Officer or Head of Finance (presenting financial results and detailed financial commentary) · 2026-09-18. On tariffs, the number has been stable at around €4 million annually since last year's call, cushioned by roughly 80% of U.S. revenue being manufactured locally. There is one honest point of agreement with the global read: “we see a slowdown in companion in the U.S.” — Paul Martingell, Executive (likely CEO or CFO) leading financial and strategic updates · 2026-09-18 Yet Virbac still posted U.S. double-digit growth. That is the agility argument, and it is genuinely company-specific rather than sector echo.

Capital allocation is the real edge — and the real bet

The most distinctive thread is what Virbac refuses to do. Asked about buybacks, Habib was categorical: “we are really favoring external growth to other type of capital allocation such as share buyback.” — Habib Ramdani, Chief Financial Officer or Head of Finance (presenting financial results and detailed financial commentary) · 2026-09-18 That gives external growth and bolt-on acquisition a status few mid-caps grant them, and the balance sheet enables it — up to roughly 2x leverage, possibly 2.5x, is on the table.

We've stated in the past up to 2, absolutely no problem. We would definitely go there. We can even go above that, 2.5. Going above 3 will require a very solid... we cannot exclude it, obviously, if we have a very strategic deal that makes a lot of sense...
Habib Ramdani, Chief Financial Officer or Head of Finance (presenting financial results and detailed financial commentary) · 2026-09-18

The H1 licensing deals (Porus One, Vetcare) are small — low double-digit millions — but structured with an option to acquire, and growth- and margin-accretive from year one. Meanwhile industrial transformation keeps capex above €100 million for "a few years," funding the pet-food internalization and site modernizations already flagged back in 2024. Cash generation of around €80 million for 2026 is the fuel.

What is actually new

New: the phased Thyronorm rollout, with the majority of Europe transferring to direct Virbac ownership in 2027, stretching the acquisition's contribution across years rather than a single step. New: the two option-to-buy licensing deals. New: the move to three operating regions to sharpen customer closeness. Recurring: the Australia-driven parasiticide drag, the milestone 20% margin ambition articulated under prior CEO Sébastien Huron (“there is no reason why Virbac should not be at or above the average profitability level of the animal health market... we have targeted 20%.” — Sébastien Huron, Chief Executive Officer · 2024-09-16), and even product discontinuation one-offs, which Habib sized at "0.3, 0.4 points of profitability impact for this semester." The takeaway: the headline beat is pleasant, but the recurring seasonality question will keep capping the multiple into H2. What deserves a fresh look is a mid-cap compounding above 7% with a hedged cost base, an underleveraged balance sheet, and a management that has told you exactly where the next euro of capital goes — acquisitions, not buybacks. That is a clean, unusual alignment of words and wallet.